Ablynx extends agreement with Wyeth

Nutrition & Food Science

ISSN: 0034-6659

Article publication date: 23 May 2008

Citation

(2008), "Ablynx extends agreement with Wyeth", Nutrition & Food Science, Vol. 38 No. 3. https://doi.org/10.1108/nfs.2008.01738cab.015

Publisher

:

Emerald Group Publishing Limited

Copyright © 2008, Emerald Group Publishing Limited


Ablynx extends agreement with Wyeth

Article Type: Food Facts From: Nutrition & Food Science, Volume 38, Issue 3.

GHENT, Belgium, December 20, 2007 Ablynx [Euronext Brussels: ABLX], a pioneer in the discovery and development of Nanobodies®, a novel class of antibody-derived therapeutic proteins, announced today that its TNF-alpha partnership with Wyeth Pharmaceuticals has been extended for another year. Wyeth and Ablynx are collaborating to discover and develop novel Nanobody®-based therapeutics against TNF-alpha. Wyeth has exclusive rights to develop and commercialise the anti-TNF-alpha Nanobodies® developed under the collaboration.